Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs 'real-world'.
Wern Yew DingJose Miguel Rivera-CaravacaAlena ShantsilaFrancisco MarinDhiraj GuptaVanessa RoldánGregory Yoke Hong LipPublished in: International journal of clinical practice (2020)
Vitamin K antagonist-treated AF patients with CKD are exposed to significant annual rates of major adverse events including all-cause mortality. This risk may be under-appreciated in the idealised environment of randomised controlled trials.